New cancer drug extends survival in advanced trials

Fuente: Arab News · salud · Arabia Saudí, Arabia Saudí

New cancer drug extends survival in advanced trials

In a recent late-stage clinical trial, pharmaceutical giant Merck announced that its experimental cancer treatment, sacituzumab tirumotecan—also known as sac-TMT—demonstrated the ability to help patients with advanced stomach and esophageal cancers live longer when compared directly against standard physician-selected chemotherapy options. These traditional treatments included medications such as trifluridine-tipiracil, irinotecan, paclitaxel, and docetaxel. The comprehensive study successfully enrolled 473 patients whose particular forms of cancer could not be successfully removed via surgery and whose conditions had unfortunately continued to progress after undergoing at least two earlier lines of treatment. Sac-TMT functions as an antibody-drug conjugate, representing a highly specialized category of targeted cancer therapy engineered specifically to deliver potent cancer-killing agents directly to malignant tumor cells while simultaneously working to minimize unintended damage to surrounding healthy tissue in the human body. Merck confirmed that sac-TMT officially met the trial’s primary objective by significantly improving overall survival rates among participants, although company representatives chose not to disclose detailed statistical data at this stage, opting instead to present those comprehensive findings at an upcoming medical conference. Interestingly, while the primary survival goal was achieved, the study did not meet its secondary endpoint of delaying overall cancer progression, as determined through independent radiological and clinical review. Furthermore, Merck reported that the drug exhibited no unexpected or new safety concerns during the evaluation period. These results build upon a series of positive late-stage trial evaluations for sac-TMT, a compound that Merck originally licensed from China-based Kelun-Biotech for commercialization and clinical development across markets located outside of Greater China. Moving forward, the pharmaceutical corporation is actively investigating the therapeutic potential of sac-TMT in clinical trials targeting multiple additional cancer types, encompassing lung, breast, and various other gastrointestinal tumors. Fuente: Arab News #Health #CancerResearch #Medicina #Merck #Oncology

También lo cubren: arabnews.com - Arab News, arabnews.com - Arab News (Arabia Saudí), arabnews.pk - Arab News Pakistan, arabnews.pk - Arab News Pakistan (Arabia Saudí).

🔗 Leer la noticia completa en Arab News

Ver más en NewsToday